Skip to content
PeptideAI
In vitro onlyimmuneinflammationlongevity

Chonluten

Bronchopulmonary tripeptide aimed at respiratory epithelium, used in short courses by people with chronic bronchitis, post-viral lung symptoms or heavy environmental exposure.

Also known as Glu-Asp-Gly, EDG, lung Cytogen, bronchopulmonary tripeptide, Chonluten

In vitro only — Cell or tissue studies. A mechanism, not yet an effect in a living body.

The published support is bronchial epithelial cell-culture work from Khavinson's institute showing restored proliferation and differentiation markers in aged cells. There are no human respiratory trials and no independent replication of the tissue-specificity claim.

How it works

Chonluten is Glu-Asp-Gly, structurally the last three residues of Epitalon's Ala-Glu-Asp-Gly, which is a detail worth noticing: it means the pineal tetrapeptide and the lung tripeptide differ by a single alanine. Khavinson's group reports that EDG restores proliferative activity in aged bronchial epithelial cultures, increases expression of differentiation markers and reduces inflammatory cytokine output. The tissue specificity claim - that one residue redirects the peptide from pineal to lung - is the single most conceptually demanding claim in the entire bioregulator programme and has not been independently tested.

Targets: Bronchial epithelium, Airway inflammatory cytokines, Epithelial differentiation markers

Dosing

ProtocolDoseFrequencyRoute
Oral capsule courseBefore food.1 mg – 2 mgonce daily for 20 to 30 daysoral
Research-market injectable courseAny time of day.1 mg – 2 mgonce daily for 10 to 20 dayssubcutaneous
  • · Capsules are the primary format for this one in Russia and Eastern Europe.
  • · Standard vial-market protocol from a 20 mg vial.

Cycling

One month of capsules or ten to twenty days injectable, two to three times a year, often timed ahead of the winter respiratory season.

Work out your exact syringe units →

Pharmacology

Half-life
Not measured; a free tripeptide clears from plasma within minutes.
Onset
Nothing acute - this is not a bronchodilator and will do nothing in an attack.
Routes
oral, subcutaneous, intranasal
Molecule
Synthetic tripeptide
Sequence length
3 amino acids
Molecular weight
319.3 Da

Handling

Diluent
Bacteriostatic water
Typical mix
2 or 3 mL
Vial sizes
20 mg
Lyophilised
Room temperature short term; fridge or freezer long term.
Reconstituted
Refrigerated, use within about 30 days.
Light sensitive
Yes — keep it out of the light

Intranasal — usable, with a caveat

A Khavinson tripeptide used nasally in that tradition, aimed at respiratory tissue. The evidence is in-vitro and Russian clinical observation rather than controlled pharmacokinetics, so the route rests on the same unmeasured assumption as the rest of that family.

Mixing

20 mg in 2 mL gives 10 mg/mL; 1 mg is 10 units on a U-100 syringe.

Side effects

  • commonInjection-site irritation— Transient, injectable route only.
  • commonNo consistent systemic side effects reported— Thin exposure data.

Do not use if

  • Do not use this in place of inhaled controller therapy for asthma or COPD - substituting an unproven peptide for a reliever or steroid inhaler is genuinely dangerous.
  • Pregnancy and breastfeeding - no data.
  • Active lung malignancy.

Combining it

  • redundanttaxorest — Taxorest is the bronchial Cytomax extract covering the same claimed territory.
  • synergythymalin-cytomax — Lung plus thymus is the conventional Russian pairing for recurrent respiratory infection.

What to monitor

  • · If you have obstructive lung disease, a home peak flow meter or spirometer before and after a course is the only honest way to see whether anything happened.
  • · Track exacerbation and infection frequency across seasons.

Legal status

Not approved for human use in the US, UK or EU; sold as a research chemical or as a supplement capsule in Russia and Eastern Europe.

References

  • Khavinson, Linkova & Tarnovskaya, short peptides regulate gene expression (preclinical)
  • Khavinson & Malinin, Gerontological Aspects of Genome Peptide Regulation (Karger monograph) (review)

Mechanism in depth

Chonluten's best evidence comes from an unexpected direction and it is not respiratory. In 2022 an Italian group at Chieti-Pescara, collaborating with Khavinson's institute, ran five Khavinson peptides through the THP-1 human monocyte-macrophage line. Chonluten specifically inhibited tumour necrosis factor production in monocytes challenged with bacterial lipopolysaccharide, and the authors linked this to the documented phenomenon of TNF tolerance - the state in which a monocyte, having been primed, mounts a blunted TNF response to a subsequent stimulus. All five peptides suppressed LPS-driven TNF and IL-6 in terminally differentiated THP-1 cells and reduced adhesion of those cells to activated endothelium. That is a specific, mechanistically coherent anti-inflammatory result, in a human cell line, published in a Western journal, with the wet work done outside Russia. It is the single most credible bench result in the whole Khavinson catalogue. It also has nothing directly to do with bronchial epithelium. The airway claims - restored proliferation and differentiation markers in aged bronchial epithelial culture, reduced local cytokine output - come from Khavinson's institute and I could not retrieve them as discrete indexed papers. The structural point in the Core record is worth keeping in view: Glu-Asp-Gly is Epitalon's Ala-Glu-Asp-Gly minus the alanine. One residue is supposed to redirect a peptide from pineal gland to lung. That is the most conceptually demanding claim in the programme, and the THP-1 result, where Chonluten behaves much like the others, does not support it.

What usually goes wrong

The dangerous scenario with Chonluten is straightforward: someone with asthma treats the peptide as a controller, drifts off their inhaled corticosteroid, and has an exacerbation. This compound is not a bronchodilator and does nothing in an attack. Reliever and controller inhalers stay exactly as they are. The second problem is the tissue-specificity story: the best evidence for this peptide is anti-inflammatory action in monocytes, not anything bronchial, and the one-residue-changes-the-organ claim is asserted rather than demonstrated. Third, the sequence itself: I could not verify Glu-Asp-Gly against an independent index, so even the identity of the molecule you are buying rests on vendor and review material.

Bloodwork worth running

MarkerWhenWhy it matters
Eosinophil count and total IgEBaseline. Eosinophils on a CBC differential cost nothing.If you are using this for asthma or allergic airway disease, these tell you what phenotype you have, and the type-2 inflammatory phenotype is the one with genuinely effective targeted therapy. It is the test that reveals a treatable disease being treated with a research peptide.Act if: A blood eosinophil count above 0.3 x10^9/L with airway symptoms identifies a phenotype that responds to inhaled corticosteroids and, in severe cases, to biologics. That is the conversation to have.
hs-CRPBaseline and four to six weeks after a course, away from any infection or hard training.The verified mechanism is TNF and IL-6 suppression, and CRP is the cheap downstream readout of IL-6. This is the one marker with a mechanistic reason to move on this compound.Act if: No human data supports an expected magnitude. If your baseline is under 1 mg/L there is nothing to lower.
Home peak flow or a cheap handheld spirometer FEV1One week before the course and one week starting two weeks after it ends.Not bloodwork, but it is the only honest objective measure for a respiratory claim and it costs less than a single vial. Twice-daily readings for a week give you a real baseline.Act if: A drop in peak flow to below 80 percent of your personal best means your airway disease is deteriorating and needs proper treatment escalation, not another peptide course.

Pharmacokinetics

Metabolism
Aminopeptidase cleavage to glutamate, aspartate and glycine - three of the most abundant free amino acids in the body, which is part of why the safety profile is quiet and part of why the pharmacological claim is demanding.
Elimination
Renal filtration of fragments.

Receptor targets

  • TNF-alpha production in LPS-stimulated human monocytes — No binding data; an expression and secretion endpoint

    Inhibited, with the authors attributing it to induction of TNF tolerance. The most specific and best-published effect this peptide has.

  • IL-6 release from terminally differentiated THP-1 macrophages

    Suppressed, alongside the other Khavinson peptides tested.

  • Monocyte adhesion to LPS-activated endothelium

    Reduced, which is a genuine anti-inflammatory readout rather than a marker change.

  • Mitogen-activated cytoplasmic kinases

    Increased tyrosine phosphorylation reported across the peptide set - the proposed proximal signalling event.

  • Bronchial epithelium

    Claimed restoration of proliferative and secretory function in aged bronchial epithelial culture. I could not retrieve this as a discrete indexed study; treat it as unverified.

What to expect, and when

Nothing acute. This does not open an airway and will do nothing in an exacerbation. Days one to twenty during an injectable course, or across a month of capsules: no perceptible change expected. Weeks four to six: the window where an hs-CRP retest or a peak-flow comparison would carry information, and no change is the honest expectation. Seasons: the claim people actually buy it on is fewer or milder winter respiratory infections, and judging that requires a written log across two winters rather than a recollection.

Stacking and comparisons

Chonluten plus Thymalin is the conventional Russian pairing for recurrent respiratory infection - lung plus thymus - and it is convention. Chonluten plus Taxorest is duplication, since Taxorest is the bronchial Cytomax. The stack that matters is the one people leave out: if you have asthma or COPD, your inhaled controller is not optional and no peptide substitutes for it. If you want an adjunct with actual randomised data for exacerbation frequency, that conversation is about inhaled corticosteroid adherence, vaccination, and in some phenotypes azithromycin or a biologic - not about peptides.

Against inhaled corticosteroids for airway disease: no comparison exists. ICS reduce exacerbations and mortality in randomised trials with tens of thousands of patients. Against Taxorest: Chonluten is the defined synthetic and Taxorest the undefined extract; the synthetic is the more rational purchase. Against N-acetylcysteine for chronic bronchitis: NAC at least has randomised exacerbation data to argue about. Against the rest of the Cytogens: Chonluten arguably has the best-published bench result of any of them thanks to the Italian collaboration, and it is an immunological result rather than a respiratory one.

Rough cost

$35–$130/month. One 20 mg vial per injectable course, or a month of capsules at the Eastern European retail price. Indicative pricing, not verified against vendor listings in this session.

Genuinely uncertain

  • The Glu-Asp-Gly sequence is stated consistently in Khavinson-derived material but Chonluten has no PubMed supplementary-concept record, so I could not verify the sequence independently. Flagged as unverified.
  • No pharmacokinetic data of any kind by any route.
  • The bronchial epithelial cell-culture work that gives this peptide its respiratory label could not be retrieved as a discrete indexed paper in this session.
  • No human respiratory data exists - no spirometry, no exacerbation rate, no symptom score.
  • The claim that removing one alanine from Epitalon redirects the peptide from pineal gland to lung is unreplicated and is not supported by the monocyte work, where Chonluten behaves similarly to the others.
  • Oral absorption of the intact tripeptide is plausible via PepT1 but has never been demonstrated.
  • Intranasal dosing has no absorption or safety data at all.
  • Cost figures are indicative estimates and were not verified against live vendor listings in this session.

Papers